

BIOCON BIOLOGICS FRANCE S.A.S**BALANCE SHEET AS AT MARCH 31, 2026**

(All amounts in EUR Thousands, except share data and unless otherwise stated)

	<u>Notes</u>	<u>March 31, 2026</u>	<u>March 31, 2025</u>
ASSETS			
Non-current assets			
Property, plant and equipment	1	126	155
Right to use assets		388	569
Deferred tax asset (net)		17	-
Total non-current assets		531	724
Current assets			
Inventories	2	9,684	12,587
Financial assets			
(i) Trade receivables	3	12,818	9,424
(ii) Cash and cash equivalents	4	5,661	6,641
(iii) Other Financial Asset	5	1	1
Other current assets	6	759	171
Total current assets		28,923	28,824
TOTAL		29,454	29,548
EQUITY AND LIABILITIES			
Equity			
Equity share capital	7	1	1
Other equity	8	1,748	1,444
Total equity		1,749	1,445
Non-current liabilities			
Lease liabilities		256	432
Total current liabilities		256	432
Current liabilities			
Financial liabilities			
(i) Trade payables	9	26,529	26,495
(ii) Lease liability		157	153
Income-tax liability (net)		12	365
Provisions	10	225	372
Other current liabilities	11	527	287
Total current liabilities		27,450	27,672
TOTAL		29,454	29,548

BIOCON BIOLOGICS FRANCE S.A.S**STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED MARCH 31, 2026**

(All amounts in EUR Thousands, except share data and unless otherwise stated)

	<u>Notes</u>	Year ended March 31, 2026	Year ended March 31, 2025
Income			
Revenue from operations	12	73,274	74,171
Other operating income	13	454	52
Total revenue		73,728	74,223
Expenses			
Purchases of traded goods	14	51,179	64,466
Changes in inventories of traded goods	15	2,903	(5,181)
Employee benefits expense	16	6,541	6,019
Depreciation & Amortisation Expense	17	189	79
Finance costs	18	37	23
Other expenses	19	11,385	7,363
Total expenses		72,234	72,769
Exceptional items		25	-
Profit before tax		1,469	1,454
Tax expense			
Current tax		1,182	275
Deferred Tax		(17)	88
Total tax expense		1,165	363
Profit for the year		304	1,091

BIOCON BIOLOGICS FRANCE S.A.S**STATEMENT OF CASH FLOWS FOR THE YEAR ENDED MARCH 31, 2026**

(All amounts in EUR Thousands, except share data and unless otherwise stated)

	Year ended March 31, 2026	Year ended March 31, 2025
I Cash flows from operating activities		
Profit after tax	304	1,091
<u>Adjustments to reconcile profit before tax to net cash flows:</u>		
Depreciation and amortisation (net)	189	79
Unrealised foreign exchange loss	(422)	52
Interest expense	37	23
Interest income	(32)	-
Tax expense	1,165	363
Operating profit before working capital changes	1,241	1,608
Movements in working capital		
(Increase)/Decrease in trade receivables	(3,387)	7,260
Decrease/(increase) in trade inventories	2,903	(5,181)
(Increase) in loans and advances and other assets	(588)	(171)
Increase in trade payable, other liabilities and provisions	127	2,476
Cash generated from operations	296	5,992
Direct taxes paid	(1,542)	(116)
Net cash flow (used in)/generated from operating activities	(1,246)	5,876
II Cash flows from investing activities		
Purchase of tangible assets	-	(155)
Interest income	32	-
Net cash flow generated/(used) from investing activities	32	(155)
III Cash flows from financing activities		
Repayment of lease liabilities	(188)	(87)
Net cash flow (used in) financing activities	(188)	(87)
IV Net increase in cash and cash equivalents (I + II + III)	(1,402)	5,634
V Effect of exchange differences on cash and cash equivalents held in foreign currency	422	(52)
VI Cash and cash equivalents at the beginning of the year	6,641	1,059
VII Cash and cash equivalents at the end of the year (IV + V + VI)	5,661	6,641
Reconciliation of cash and cash equivalents as per statement of cash flow		
Cash and cash equivalents		
Balances with banks - on current accounts	4,861	6,641
	5,661	6,641
Total cash and cash equivalents [Refer note 3]	5,661	6,641

BIOCON BIOLOGICS FRANCE S.A.S**NOTES TO FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026****(All amounts in EUR Thousands, except share data and unless otherwise stated)**

1. Computer	Computer and Accessories	Total
Gross carrying amount		
At March 31, 2025	155	155
Additions	-	-
At March 31, 2026	155	155
Accumulated amortisation		
At March 31, 2025	-	-
Amortisation for the quarter	29	29
At March 31, 2026	29	29
Net carrying amount		
At March 31, 2025	155	155
At March 31, 2026	126	126

BIOCON BIOLOGICS FRANCE S.A.S**NOTES TO FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026**

(All amounts in EUR Thousands, except share data and unless otherwise stated)

	March 31, 2026	March 31, 2025
2. Inventories		
Finished Goods	9,684	12,587
	9,684	12,587
3. Trade receivables		
Other Receivables		
Outstanding for a period less than six months from the date they are due for payment	12,830	9,426
Unsecured, considered good	(11)	-
Allowance for credit loss	12,818	9,424
4. Cash and cash equivalents		
Balances with banks:		
On current accounts	4,861	6,641
Deposit accounts	800	-
	5,661	6,641
5 . Other Financial Assets		
Other Receivables	1	1
	1	1
6. Other current assets		
Advance to suppliers	-	7
Prepayments	3	6
VAT Receivable	756	158
	759	171
7. Share capital		
Authorised		
Issued, subscribed and fully paid-up		
1,000 Equity shares of EUR 1 each	1	1
	1	1
8. Other equity		
Surplus in the statement of profit and loss		
Balance as per the last financial statements	1,444	353
Profit for the period	304	1,091
Net surplus in the statement of profit and loss	1,748	1,444
Total other equity	1,748	1,444
9. Trade payables	26,530	26,495
10. Provisions		
Current		
Compensated absences	225	372
	225	372
11. Other liabilities		
(a) Current liabilities		
Statutory liabilities	527	287
Advance from supplier	-	-
	527	287

BIOCON BIOLOGICS FRANCE S.A.S**NOTES TO FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026**

(All amounts in EUR Thousands, except share data and unless otherwise stated)

	Year ended March 31, 2026	Year ended March 31, 2025
12. Revenue from operations		
Sale of Products		
Traded Goods	71,837	72,716
Sale of Services		
Support service cross charge to Group Companies	1,437	1,455
	73,274	74,171
13. Other operating income		
Foreign exchange fluctuations, net	422	52
Interest income	32	-
	454	52
14. Purchase of traded goods	51,179	64,466
15. Changes in inventories of traded goods		
Inventory at the beginning of the year		
Traded goods	12,587	7,406
Inventory at the end of the year		
Traded goods	9,684	12,587
	2,903	(5,181)
16. Employee benefits expense		
Salaries, wages and bonus	6,498	5,992
Employee stock compensation expense	43	11
Staff welfare expenses	-	16
	6,541	6,019
17. Depreciation		
Amortisation of right to use assets	160	-
Depreciation of tangible assets	29	-
	189	-
18. Finance Costs		
Interest on lease obligation	37	23
	37	23
19. Other expenses		
Rates and taxes	241	43
Rent	244	137
Legal and professional fees	474	467
Repair and Maintenance	376	144
Travelling and conveyance	269	483
Selling expenses	688	874
Sales promotion expenses	8,706	4,793
Printing and stationery	75	5
Communication expenses	1	3
Miscellaneous expenses	300	437
Insurance Charges	-	(24)
Provision/(reversal) for doubtful debts, net	11	-
	11,385	7,362